This randomized clinical trial aims to investigate the effects of multicomponent concurrent exercise training associated or not with taurine supplementation on intramuscular fat infiltration, physical performance, transcriptomic profile, and metabolomic profile in older women with obesity. Forty women aged 60 to 75 years with obesity will be randomized into four groups: control, exercise, taurine, and exercise plus taurine. The intervention will last 16 weeks. Outcomes include magnetic resonance imaging, body composition, muscle biopsy, blood biomarkers, functional capacity tests, transcriptomic analysis, and metabolomic analysis.
Aging and obesity are associated with important physiological, metabolic, and functional alterations, including increased intramuscular fat infiltration, also known as myosteatosis. Intramuscular fat infiltration is associated with reduced muscle quality, impaired physical performance, metabolic dysfunction, insulin resistance, and increased risk of morbidity and mortality in older adults. Physical exercise is recognized as an important non-pharmacological strategy to improve muscle function and metabolic health. In addition, taurine supplementation has demonstrated anti-inflammatory and metabolic effects that may contribute to the reduction of intramuscular fat accumulation and improvement of skeletal muscle health. However, the synergistic effects of concurrent exercise training associated with taurine supplementation on intramuscular fat infiltration and molecular mechanisms involved in older women with obesity are still unclear. Therefore, this randomized clinical trial aims to investigate the effects of physical exercise associated or not with taurine supplementation on intramuscular fat infiltration, physical performance, body composition, transcriptomic profile, and metabolomic profile in older women with obesity. Forty women aged 60 to 75 years with obesity (Body mass index - BMI between 30 and 40 kg/m²) will be randomized into four groups: * Control group; * Exercise group; * Taurine supplementation group; * Exercise plus taurine supplementation group. The intervention will last 16 weeks. Participants allocated to exercise groups will perform supervised concurrent exercise training three times per week, including resistance and aerobic exercises. Participants allocated to taurine groups will receive 3 grams per day taurine supplementation. Assessments performed before and after the intervention will include magnetic resonance imaging for intramuscular fat evaluation, body composition by dual-energy X-ray absorptiometry (DXA), muscle biopsy, blood biomarkers, indirect calorimetry, functional capacity tests, muscle strength, transcriptomic analysis, and metabolomic analysis. This study may contribute to the development of innovative non-pharmacological strategies for obesity, aging, and intramuscular fat infiltration management.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Participants will perform supervised concurrent exercise training three times per week for 16 weeks. Exercise sessions will include warm-up, resistance exercises, aerobic training, and stretching exercises, according to American College of Sports Medicine (ACSM) recommendations for older adults.
Participants will receive 3 grams per day taurine supplementation administered orally in capsules for 16 weeks.
Participants will receive placebo capsules identical in appearance to taurine capsules.
Escola de Educação Física e Esporte de Ribeirão Preto, Ribeirão Preto, São Paulo.
Ribeirão Preto, São Paulo, Brazil
Change from Baseline in Intramuscular Fat Fraction Assessed by Magnetic Resonance Imaging (Dixon Technique)
Intramuscular fat fraction assessed by magnetic resonance imaging (MRI) using the Dixon technique, reported as percentage (%) of fat within the muscle tissue. Change is calculated from baseline to Week 16.
Time frame: Baseline and 16 weeks
Change from baseline in skeletal muscle transcriptomic profile
Skeletal muscle biopsy samples will be analyzed using RNA sequencing to characterize changes in the skeletal muscle transcriptomic profile following the intervention.
Time frame: Baseline and 16 weeks
Change from baseline in plasma metabolomic profile
Plasma samples will be analyzed using untargeted metabolomic analysis to evaluate changes in the plasma metabolomic profile after 16 weeks of intervention.
Time frame: 16 weeks
Change from baseline in plasma taurine concentration
Plasma taurine concentration will be measured before and after the 16-week intervention.
Time frame: Baseline and 16 weeks
Change from baseline in Timed Up and Go test time
Functional mobility will be assessed using the Timed Up and Go test.
Time frame: Baseline and 16 weeks
Change from baseline in handgrip strength
Handgrip strength will be assessed using a hand dynamometer.
Time frame: Baseline and 16 weeks
Change from baseline in chair stand test performance
Lower-body functional performance will be assessed using the Chair Stand Test.
Time frame: Baseline and 16 weeks
Change from baseline in forearm flexion test performance
Upper-body muscular endurance will be assessed using the Forearm Flexion Test.
Time frame: Baseline and 16 weeks
Change from baseline in isokinetic knee extensor peak torque
Peak torque of the knee extensor muscles will be measured using an isokinetic dynamometer.
Time frame: Baseline and 16 weeks
Change from baseline in fat-free mass
Fat-free mass will be assessed by dual-energy X-ray absorptiometry.
Time frame: Baseline and 16 weeks
Change from baseline in fat mass
Fat mass will be assessed by dual-energy X-ray absorptiometry.
Time frame: Baseline and 16 weeks
Change from baseline in fasting blood glucose concentration
Fasting blood glucose concentration will be measured using blood samples collected after an overnight fast.
Time frame: Baseline and 16 weeks
Change from baseline in fasting insulin concentration
Fasting insulin concentration will be measured using blood samples collected after an overnight fast.
Time frame: Baseline and 16 weeks
Change from baseline in total cholesterol concentration
Total cholesterol concentration will be measured using fasting blood samples.
Time frame: Baseline and 16 weeks
Change from baseline in high-density lipoprotein cholesterol concentration
High-density lipoprotein cholesterol concentration will be measured using fasting blood samples.
Time frame: Baseline and 16 weeks
Change from baseline in low-density lipoprotein cholesterol concentration
Low-density lipoprotein cholesterol concentration will be measured using fasting blood samples.
Time frame: Baseline and 16 weeks
Change from baseline in triglyceride concentration
Triglyceride concentration will be measured using fasting blood samples.
Time frame: Baseline and 16 weeks
Change from baseline in resting metabolic rate
Resting metabolic will be assessed by indirect calorimetry after an overnight fast.
Time frame: Baseline and 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.